LivaNova (LIVN) Cash from Financing Activities (2015 - 2026)
LivaNova (LIVN) posted Cash from Financing Activities of -$94.2 million for Q1 2026, down 49.87% sequentially from -$62.9 million in Q4 2025, and down 2031.76% YoY from $4.9 million in Q1 2025.
LivaNova (LIVN) Cash from Financing Activities (2015 - 2026) Analysis & Trends
LivaNova has reported Cash from Financing Activities for 12 years, with the latest figure at -$94.2 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 2031.76% year-over-year to -$94.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$375.5 million (down 1531.33% YoY) and the FY2025 annual result came in at -$285.7 million, down 1639.86% from the prior year.
- Cash from Financing Activities eased to -$94.2 million in Q1 2026 per LIVN's latest filing, from -$62.9 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $214.9 million in Q1 2022 and troughed at -$209.0 million in Q2 2025.
- A 5-year average of -$3.5 million and a median of -$4.4 million in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities jumped 2680.18% in 2022, then slumped 2031.76% in 2026.
- Over 5 years, Cash from Financing Activities stood at -$1.7 million in 2022, then slumped by 202.84% to -$5.0 million in 2023, then jumped by 31.37% to -$3.4 million in 2024, then sank by 1725.9% to -$62.9 million in 2025, then plunged by 49.87% to -$94.2 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$94.2 million, -$62.9 million, and -$9.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.91 Bn | 193.31 Bn | 7.27 Bn | -3.52 Bn |
| 2 | Stryker | 127.59 Bn | 124.11 Bn | 4.50 Bn | -95.00 Mn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 73.24 Bn | 72.70 Bn | 3.85 Bn | -410.00 Mn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | -300,000.00 |
| 6 | Dexcom | 34.38 Bn | 32.44 Bn | 830.00 Mn | -607.30 Mn |
| 7 | GE HealthCare Technologies | 33.96 Bn | 31.85 Bn | 2.18 Bn | -236.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | -1.34 Bn |
| 9 | Steris | 23.08 Bn | 22.60 Bn | 684.20 Mn | -213.50 Mn |
| 10 | LivaNova | 4.29 Bn | 3.77 Bn | 273.67 Mn | -56.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -56.45 Mn |
| Jun 30, 2026 | -56.45 Mn |
| Mar 31, 2026 | -94.25 Mn |
| Mar 31, 2026 | -94.25 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Dec 31, 2025 | -62.88 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Sep 30, 2025 | -9.37 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Jun 30, 2025 | -208.98 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Mar 31, 2025 | -4.42 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Dec 31, 2024 | -3.44 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -11.87 Mn |
| Mar 31, 2024 | 37.15 Mn |
| Mar 31, 2024 | 37.15 Mn |